Comprehensive Safety Tests Published on Ruyan(R) Smoking Al...(where theyotherwise cannot smoke by law ...),Health

Date:10/28/2008

where they otherwise cannot smoke by law, regulation or common courtesy. Ruyan is the only manufacturer of E-cigarette pursuant to Mr. Hon's patents and Ruyan America is the only Company providing E-cigarettes, E-cigars, E-pipes, their cartridges and accessories to distributors and retailers in concert with safety test results, product liability insurance, detailed ingredient lists, documentation of proprietary intellectual property and the support of a $4 million Direct Response Television campaign. Information about the company and its products can be found at http://www.ruyanamerica.com and the company's DRTV infomercial can be viewed at http://www.nathanandjamesgroup.com.

Warning: Be advised that nicotine is addictive. The Ruyan products have not been evaluated by the US FDA. They are not intended to be drug products that diagnose, treat, cure or mitigate any disease or condition. Do not use these products if you are under the age of 21; if you are a non-smoker, if you have a demonstrated sensitivity to nicotine or any combination of common inhalants; or if you are pregnant or nursing.

For Additional Information, Please Contact:

William P. Bartkowski, President

Ruyan America, Inc.

612.605.8616

billb@ruyanamerica.com

'/>"/>

SOURCE Ruyan America, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
2. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
3. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
7. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
8. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
11. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy